

Supplementary Table I. SLE patient characteristics and attitudes in relation to preferences for CYC treatment* .

Characteristic	Unwilling to receive CYC (n=69)	Willing to receive CYC (n=224)	<i>p</i> [†]
<i>Demographic characteristics</i>			
Recruitment site, n(%)			0.289
U Chicago	38 (55.1)	107 (47.8)	
U Pittsburgh	31 (44.9)	117 (52.2)	
Age, mean ± SD years	44.6 (16.3)	45.6 (12.9)	0.597
Race, n(%)			<0.001
White	20 (29.0)	141 (63.0)	
African-American	49 (71.0)	83 (37.1)	
Sex, n(%) F	65 (94.2)	211 (94.2)	1.000
Education, n(%)			0.168
Less than HS graduate	5 (7.3)	8 (3.6)	
HS graduate	17 (24.6)	46 (20.5)	
More than HS graduate	47 (68.1)	170 (75.9)	
Income, n(%)			<0.001
<\$10000	21 (32.3)	35 (15.6)	
\$10001-30000	21 (32.3)	41 (18.3)	
\$30001-50000	9 (13.9)	36 (16.1)	
>\$50000	14 (21.5)	109 (48.7)	
Employed, n(%)	31 (44.9)	108 (48.2)	0.633
Medical insurance, n(%)			0.004
Without Private	34 (49.3)	68 (30.4)	
With Private	35 (50.7)	156 (69.6)	
Marital status, n(%)			<0.001
Married	19 (27.5)	125 (55.8)	
Other (Single, Divorced, Widowed)	50 (72.5)	99 (44.2)	
<i>Clinical Characteristics</i>			
SLEDAI, mean ± SD	3.5 (3.4)	3.4 (2.9)	0.810
SLICC Damage Index, mean ± SD	1.8 (2.4)	1.4 (1.6)	0.092
Disease duration, mean ± SD months	151.5 (136.3)	136.3 (117.2)	0.365
[#] Immunosuppressants used in past, n(%)			0.689
0	38 (55.1)	118 (52.7)	
1	17 (24.6)	53 (23.7)	
2	8 (11.6)	34 (15.2)	
3	2 (2.9)	11 (4.9)	
≥4	4 (5.8)	8 (3.6)	
[#] Immunosuppressants currently being used, n(%)			0.859
0	6 (8.7)	10 (4.5)	
1	32 (46.4)	116 (51.8)	
≥2	31 (44.9)	98 (43.8)	
Charlson Comorbidity Index, mean ± SD	2.2 (1.4)	2.0 (1.2)	0.166
CES-D, mean ± SD	18.4 (13.2)	18.0 (12.4)	0.816
<i>Perceptions about CYC</i>			
Familiarity with CYC, mean ± SD	0.29 (0.6)	0.46 (0.7)	0.074
Perception of effectiveness of CYC, mean ± SD	18.1 (3.5)	22.2 (3.4)	<0.001
Perception of risk of CYC, mean ± SD	11.6 (2.3)	10.5 (2.2)	0.001
<i>Beliefs and attitudes</i>			
Prayer efficacy, n(%)			0.065
No help	4 (5.8)	27 (12.1)	
Some help	14 (20.3)	57 (25.5)	
Much help	51 (73.9)	140 (62.5)	
Prayer frequency, n(%)			0.249
Never	8 (11.6)	33 (14.7)	
Monthly	11 (15.9)	32 (14.3)	
Weekly	9 (13.0)	48 (21.4)	
Daily	41 (59.4)	111 (49.6)	
DOSPERT, mean ± SD	16.5 (5.1)	16.8 (4.2)	0.563
Locus of control, mean ± SD			
Internal	24.6 (5.3)	24.7 (5.17)	0.898
Chance	17.6 (5.5)	18.1 (5.4)	0.510
Powerful others	23.7 (5.5)	24.6 (8.4)	0.432

Supplementary Table I. (continued)

Characteristic	Unwilling to receive CYC (n=69)	Willing to receive CYC (n=224)	<i>p</i> [†]
<i>Physician-patient relationship characteristics</i>			
Prefer seeing a physician of own race, n(%)			0.365
Very unimportant	38 (55.1)	128 (57.1)	
Unimportant	16 (23.2)	69 (30.8)	
Neutral	10 (14.5)	22 (9.8)	
Important	3 (4.4)	5 (2.2)	
Very important	2 (2.9)	0 (0.0)	
Prefer seeing a physician of own sex, n(%)			0.628
Very unimportant	30 (43.5)	108 (48.2)	
Unimportant	19 (27.5)	57 (25.5)	
Neutral	12 (17.4)	26 (11.6)	
Important	5 (7.3)	20 (8.9)	
Very important	3 (4.4)	13 (5.8)	
Prefer seeing a physician of own age, n(%)			0.482
Very unimportant	34 (49.3)	121 (54.0)	
Unimportant	23 (33.3)	68 (30.4)	
Neutral	8 (11.6)	27 (12.1)	
Important	4 (5.8)	7 (3.1)	
Very important	0 (0.0)	1 (0.5)	
Relationship duration, mean ± SD years	4.96 (4.77)	5.06 (5.17)	0.880
Duration of follow-up at clinic, mean ± SD years	7.8 (7.8)	7.7 (6.9)	0.883
Physician's PDM style, mean ± SD	66.4 (27.5)	73.2 (23.1)	0.094
Trust in physicians, mean ± SD	36.0 (8.2)	39.4 (8.1)	0.003
Perceived discrimination, mean ± SD	11.0 (3.3)	9.6 (3.3)	0.005

*Among patients with no history of taking CYC.

[†]Significance level of the χ^2 (or Wilcoxon's rank sum test) statistic for categorical variables and 2-tailed *t*-test for continuous variables.

CES-D: Center for Epidemiologic Studies Depression Scale; CYC: Cyclophosphamide; DOSPERT: Domain-specific risk attitude scale; HS: High School; PDM: Participatory decision-making; SLEDAI: SLE Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics.

Supplementary Table II. Patient characteristics and attitudes in relation to preferences for participation in a RCT, involving a new, experimental medication*.

Characteristic	Unwilling to participate in a Lupus RCT (n=81)	Willing to participate in a Lupus RCT (n=245)	<i>p</i> [†]
<i>Demographic characteristics</i>			
Recruitment site, n(%)			0.477
U Chicago	46 (56.8)	128 (52.2)	
U Pittsburgh	35 (43.2)	117 (47.8)	
Age, mean ± SD years	42.7 (14.8)	45.0 (12.7)	0.175
Race, n(%)			<0.001
White	27 (33.3)	145 (59.2)	
African-American	54 (66.7)	100 (40.8)	
Sex, n(%) F	76 (93.8)	231 (94.3)	1.000
Education, n(%)			0.134
Less than HS graduate	7 (8.6)	9 (3.7)	
HS graduate	19 (23.5)	51 (20.8)	
More than HS graduate	55 (67.9)	185 (75.5)	
Income, n(%)			0.012
<\$10000	22 (28.2)	44 (18.1)	
\$10001-30000	18 (23.1)	51 (21.0)	
\$30001-50000	14 (18.0)	40 (16.5)	
>\$50000	22 (28.2)	106 (43.6)	
Employed, n(%)	30 (37.0)	122 (49.8)	0.046
Medical insurance, n(%)			0.001
Without Private	43 (53.1)	78 (31.8)	
With Private	38 (46.9)	167 (68.2)	
Marital status, n(%)			0.004
Married	27 (33.3)	127 (51.8)	
Other (Single, Divorced, Widowed)	54 (66.7)	118 (48.2)	

Supplementary Table II. (continued)

Characteristic	Unwilling to participate in a Lupus RCT (n=81)	Willing to participate in a Lupus RCT (n=245)	<i>p</i> [†]
<i>Clinical characteristics</i>			
SLEDAI, mean ± SD	3.4 (3.3)	3.4 (3.3)	0.952
SLICC Damage Index, mean ± SD	2.2 (1.9)	1.7 (2.2)	0.061
Disease duration, mean ± SD months	134.2 (110.0)	141.2 (119.0)	0.640
[#] Immunosuppressants used in past, n(%)			0.203
0	35 (43.2)	120 (49.0)	
1	17 (21.0)	58 (23.7)	
2	14 (17.3)	39 (15.9)	
3	11 (13.6)	12 (4.9)	
≥4	4 (4.9)	16 (6.5)	
[#] Immunosuppressants currently being used, n(%)			0.034
0	10 (12.4)	9 (3.7)	
1	42 (51.9)	125 (51.0)	
≥2	29 (35.8)	111 (45.3)	
Charlson Comorbidity Index, mean ± SD	2.4 (1.4)	2.1 (1.3)	0.087
CES-D, mean ± SD	19.3 (13.4)	17.2 (11.6)	0.167
<i>Beliefs and attitudes</i>			
Prayer efficacy, n(%)			0.140
No help	6 (7.4)	24 (9.8)	
Some help	16 (19.8)	65 (26.5)	
Much help	59 (72.8)	156 (63.7)	
Prayer frequency, n(%)			0.204
Never	10 (12.4)	31 (12.7)	
Monthly	9 (11.1)	38 (15.5)	
Weekly	14 (17.3)	54 (22.0)	
Daily	48 (59.3)	122 (49.8)	
DOSPERT, mean ± SD	16.8 (5.6)	16.7 (4.2)	0.875
Locus of control, mean ± SD			
Internal	25.7 (5.7)	24.6 (5.0)	0.107
Chance	18.7 (5.5)	18.2 (5.7)	0.494
Powerful others	23.8 (5.9)	24.4 (5.5)	0.428
<i>Physician-patient relationship characteristics</i>			
Prefer seeing a physician of own race, n(%)			0.014
Very unimportant	37 (45.7)	152 (62.0)	
Unimportant	31 (38.3)	63 (25.7)	
Neutral	8 (9.9)	24 (9.8)	
Important	4 (4.9)	5 (2.0)	
Very important	1 (1.2)	1 (0.4)	
Prefer seeing a physician of own sex, n(%)			0.316
Very unimportant	35 (43.2)	125 (51.0)	
Unimportant	24 (29.6)	60 (24.5)	
Neutral	13 (16.1)	26 (10.6)	
Important	2 (2.5)	24 (9.8)	
Very important	7 (8.6)	10 (4.1)	
Prefer seeing a physician of own age, n(%)			0.201
Very unimportant	39 (48.2)	138 (56.3)	
Unimportant	29 (35.8)	74 (30.2)	
Neutral	9 (11.1)	27 (11.0)	
Important	3 (3.7)	6 (2.5)	
Very important	1 (1.2)	0 (0.0)	
Relationship duration, mean ± SD years	5.3 (5.2)	5.2 (5.1)	0.860
Duration of follow-up at clinic, mean ± SD years	7.2 (5.8)	7.7 (7.0)	0.558
Physician's PDM style, mean ± SD	65.4 (28.1)	72.7 (22.9)	0.069
Trust in physicians, mean ± SD	37.0 (7.6)	39.4 (8.3)	0.023
Perceived discrimination, mean ± SD	10.3 (3.4)	9.6 (3.4)	0.122

*Among patients with no history of participating in a RCT.

[†]Significance level of the χ^2 (or Wilcoxon's rank sum test) statistic for categorical variables and 2-tailed *t*-test for continuous variables.

CES-D: Center for Epidemiologic Studies Depression Scale; DOSPERT: Domain-specific risk attitude scale; HS: High School; PDM: Participatory decision-making; RCT: research clinical trial; SLEDAI: SLE Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics.